Exactly one year after the company was listed on the main board of the Hong Kong Stock Exchange in October 2022, domestic vaccine company Aimei vaccines (06660.HK) promptly initiated its return-to-A-share plan.

This year's Nobel Prize once again dominated the hot topics list with the previously renowned mRNA technology. The good news is that the leading vaccine company Aimei Vaccine (06660.HK), which carries the heavyweight weapon mRNA technology platform and possesses five major technological platforms including bacterial vaccines and genetic engineering vaccines, has recently announced that the company has decided to initiate an A-share listing plan, which has been approved by the board of directors.

As a rare full industry chain vaccine group in China, Aimei Vaccine (06660) announced that its heavy single product is about to enter the harvest period. Last Thursday, the stock price rose rapidly, soaring by 4.99% for the entire day, closing at HK$49.4, with a total market value of HK$59.8 billion. Investors should closely monitor the recent trend of the stock price and make early deployments.

Aimei Vaccine (06660.HK) issued the latest announcement on August 30, stating that the company has received approval from the China Securities Regulatory Commission to issue non-publicly listed RMB ordinary shares (i.e., domestic shares) to specific entities.

Aimei Vaccine (06660) announced on the 12th that the clinical trial application for human rabies mRNA vaccine under research has been accepted by the CDE. This is the first domestic application for a clinical rabies mRNA vaccine.

On June 10th, information on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) showed that the clinical trial application for the human rabies mRNA vaccine by domestic private vaccine manufacturer Aimei Vaccine's subsidiary Lifanda Biotech has been accepted. This marks the first domestic rabies mRNA vaccine to apply for clinical trials and is expected to enter clinical trials soon.